Xortx to present at bio international convention 2022

Calgary, alberta, june 13, 2022 (globe newswire) -- xortx therapeutics inc. ("xortx" or the “company”) (nasdaq: xrtx | tsxv: xrtx | frankfurt: anu), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce its participation in the bio international convention 2022, being held june 13th through 16th, 2022. dr. allen davidoff, xortx's ceo, will present an overview on the company, including the company's progress to date and planned future regulatory and clinical activities.
XRTX Ratings Summary
XRTX Quant Ranking